Back to Main

Faculty Detail    
Director Of Integrative Translational Oncologic Pathology Research.
Co-Director of the Graduate Biomedical Sciences Doctoral Training Program (Cancer Biology).
Campus Address WTI 420B Zip 3300
Phone  205-996-1653
Other websites Google Scholar
PubMed Publication

Faculty Appointment(s)
Appointment Type Department Division Rank
Center  Comprehensive Cancer Center  Comprehensive Cancer Center Associate Professor
Primary  Pathology   Molecular & Cellular Pathology Associate Professor

Graduate Biomedical Sciences Affiliations
Cancer Biology 
Genetics, Genomics and Bioinformatics 

Biographical Sketch 
Dr. Varambally's groups research interest include understanding the molecular basis of cancer using Cancer Genomics, Bioinformatics, Biomarker Discovery, Integrative Cancer Research. His group also works in the area of therapeutic targeting. His investigations led to the identification of role, and regulation of histone methyltransferase EZH2 in multiple cancers, Transcription factor ERG biology in prostate cancer, role and regulation of collagen modifying enzyme P4HA1 and the role and regulation of de novo purine biosynthetic enzymes in multiple cancers.
Dr. Varambally is the recipient of the Inaugural American Association for Cancer Research (AACR) Team Science Award. He has published over 95 manuscripts, many of them in high impact journals like Nature, Science, NEJM, JAMA, Nature Medicine, Cancer Cell, Nature Biotechnology, PNAS and Cancer Research among others. His groups research has been tanrslationally significant and he is a highly cited researcher with over 24,300 citations and co-authored 22 articles in journals with impact factor more than 22 including in Nature (4), Science (3), Nature Medicine (3) Cancer Cell (7), New England Journal of Medicine (1) Nature Biotechnology (2), Nature Immunology (1) and JAMA (1).
Recently, his group developed a web portal for easy analyses of cancer gene expression using publicly available data (TCGA transcriptome sequencing). The portal is called "UALCAN" and the link is at:

Research/Clinical Interest
Cancer Genomics, Bioinformatics, Proteomics, Biomarker Discovery, Integrative Cancer Research and Therapeutic Targeting.

Selected Publications 
Publication PUBMEDID
Chandrashekar DS, Bashel B, Balasubramanya SAH, Creighton CJ, Rodriguez IP, Chakravarthi BVSK and Varambally S. UALCAN: A portal for facilitating tumor subgroup gene expression and survival analyses. Neoplasia (New York, N.Y.) 19(8):649-658. August 2017  28732212 
Wang X, Qiao Y, Asangani IA, Ateeq B, Poliakov A, Cieślik M, Pitchiaya S, Chakravarthi BV, Cao X, Jing X, Wang CX, Apel IJ, Wang R, Tien JC, Juckette KM, Yan W, Jiang H, Wang S, Varambally S, Chinnaiyan AM. Development of Peptidomimetic Inhibitors of the ERG Gene Fusion Product in Prostate Cancer. Cancer Cell. 2017 Apr 10;31(4):532-548.e7.  28344039 
Beltran H, Prandi D, Mosquera JM, Benelli M, Puca L, Cyrta J, Marotz C, Giannopoulou E, Chakravarthi BV, Varambally S, Tomlins SA, Nanus DM, Tagawa ST, Van Allen EM, Elemento O, Sboner A, Garraway LA, Rubin MA, Demichelis F. Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer. Nat Med. 2016 Mar;22(3):298-305.  26855148 
Ende Zhao, Tomasz Maj, Ilona Kryczek, Wei Li, Ke Wu, Lili Zhao, Shuang, Wei, Joel Crespo, Shanshan Wan, Linda Vatan, Wojciech Szeliga, Yin Wang, Yan, Liu, Sooryanarayana Varambally, Arul M. Chinnaiyan, Theodore H. Welling, Victor E., Marquez, Jan Kotarski, Yi Zhang, Rebecca Liu, Guobin Wang, Weiping Zou, Cancer mediates effector T cell dysfunction by targeting microRNAs and EZH2 via glycolysis restriction. Nat Immunol. 2016 Jan;17(1):95-103.  26523864 
Goswami MT, Chen G, Chakravarthi BV, Pathi SS, Anand SK, Carskadon SL, Giordano TJ, Chinnaiyan AM, Thomas DG, Palanisamy N, Beer DG, Varambally S. Role and regulation of coordinately expressed de novo purine biosynthetic enzymes PPAT and PAICS in lung cancer. Oncotarget. 2015 Jun 23.  26140362 
Chakravarthi B.V.S.K, Pathi S.S, Goswami M.T., Cieślik M., Zheng H., Arekapudi S.R., Jing X., Siddiqui J., Athanikar J., Carskadon S.L., Lonigro R., Kunju L.P., Chinnaiyan A.M., Palanisamy N., Varambally S. The miR-124-Prolyl Hydroxylase P4HA1-MMP1 axis plays a critical role in prostate cancer progression. Oncotarget. 2014 Aug 30;5(16):6654-69.  25115393 
Wang R, Asangani I.A., Chakravarthi B.V.S.K., Ateeq B, Lonigro R.J., Cao Q., Mani R., Camacho D.F., McGregor N., Schumann T.E.W., Jing X., Menawat R., Tomlins S.A, Zheng H., Otte A.P., Mehra R., Siddiqui J., Dhanasekaran S.M., Nyati M.K., Pienta K.J., Palanisamy N., Kunju L.P., Rubin M.A.. Chinnaiyan A.M. and Varambally S. Role of Transcriptional Co-Repressor CtBP1 in Prostate Cancer Progression. Neoplasia. Oct. 2012, 14(10): 905-14.  23097625  
Cao Q, Mani RS, Ateeq B, Dhanasekaran SM, Asangani IA, Prensner JR, Kim JH, Brenner JC, Jing X, Cao X, Wang R, Li Y, Dahiya A, Wang L, Pandhi M, Lonigro RJ, Wu YM, Tomlins SA, Palanisamy N, Qin Z, Yu J, Maher CA, Varambally S.* and Chinnaiyan A.M.* Coordinated Regulation of Polycomb Group Complexes through microRNAs in Cancer. (*senior authors). Cancer Cell. 2011 Aug 16;20(2):187-99. PMCID: PMC3157014  21840484 
Varambally S, Cao Q, Mani RS, Shankar S, Wang X, Ateeq B, Laxman B, Cao X, Jing X, Ramnarayanan K, Brenner JC, Yu J, Kim JH, Han B, Tan P, Kumar-Sinha C, Lonigro RJ, Palanisamy N, Maher CA, Chinnaiyan AM. Genomic Loss of microRNA-101 Leads to Overexpression of Histone Methyltransferase EZH2 in Cancer. Science. 2008 Dec 12;322(5908):1695-9. PMCID:PMC2684823.  19008416 
Varambally S, Yu J, Laxman B, Rhodes DR, Mehra R, Tomlins SA, Shah RB, Chandran U, Monzon FA, Becich MJ, Wei JT, Pienta KJ, Ghosh D, Rubin MA, Chinnaiyan AM. Integrative Genomic and Proteomic Analysis of Prostate Cancer Reveals Signatures of Metastatic Progression. Cancer Cell. 2005 Nov;8(5):393-406.   16286247 
Varambally S, Dhanasekaran SM, Barrette TR, Sanda MG, Ghosh D, Pienta KJ, Sewalt RGAB, Otte AP, Rubin MA, Chinnaiyan AM. The Polycomb Group Protein EZH2 is involved in Prostate Cancer Progression. Nature, (2002) 419:624-9.   11518967 

Genomics, Bioinformatics, Proteomics, Biomarker, Integrative Cancer Biology and Therapeutics.